Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163364 | 0.96 | TSHR (0.51) | TSHRMAPK1TP53POLBMAPT | |
| SCHEMBL16163128 | 0.88 | — | — | |
| SCHEMBL16163465 | 0.84 | — | — | |
| SCHEMBL16163229 | 0.83 | TSHR (0.51) | TSHRMAPK1 | |
| SCHEMBL7740571 | 0.81 | TSHR (0.56) | TSHRMAPK1TP53POLBMAPT | |
| SCHEMBL16163321 | 0.81 | TSHR (0.51) | TSHRMAPK1 | |
| SCHEMBL16163238 | 0.81 | TSHR (0.53) | TSHRMAPK1 | |
| SCHEMBL3727049 | 0.79 | TSHR (0.54) | TSHRMAPK1TP53POLBMAPT | |
| SCHEMBL14941421 | 0.79 | TSHR (0.51) | TSHRMAPK1TP53POLBMAPT | |
| SCHEMBL3738360 | 0.79 | TSHR (0.53) | TSHRMAPK1TP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809575-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2017-11-07 | — | — | US | claimed |
| EP-2776416-B1 | PHARMACEUTICAL COMPOUNDS | RE VIRAL LTD (GB) | 2016-01-13 | — | — | EP | claimed |
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | re: Viral Ltd (GB) | 2014-10-16 | — | — | US | claimed |
| US-9809575-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-2776416-B1 | PHARMACEUTICAL COMPOUNDS | RE VIRAL LTD (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | re: Viral Ltd (GB) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | CYP2S1, H1-2, CBR1 | TSHR 2037/4885MAPK1 1885/4885TP53 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.